Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial


SHITARA K., Ozguroglu M. , BANG Y., DI BARTOLOMEO M., MANDALA M., RYU M., ...More

LANCET, vol.392, no.10142, pp.123-133, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 392 Issue: 10142
  • Publication Date: 2018
  • Doi Number: 10.1016/s0140-6736(18)31257-1
  • Title of Journal : LANCET
  • Page Numbers: pp.123-133

Abstract

Background Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastrooesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.